biomarkers in chronic fatigue syndrome evaluation of natural killer cell function and dipeptidyl peptidase ivcd26生物标志物在慢性疲劳综合症的评价自然杀伤细胞功能和dipeptidyl肽酶ivcd26.pdf

Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 1,2,3 . 1,2 1 1,2 3 3 Mary A. Fletcher * , Xiao R. Zeng , Kevin Maher , Silvina Levis , Barry Hurwitz , Michael Antoni , Gordon Broderick4, Nancy G. Klimas1,2,3. 1 Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 2 Miami Veterans Health Care Center, Miami, Florida, United States of America, 3 Department of Psychology, University of Miami, Coral Gables, Florida, United States of America, 4 Department of Medicine, University of Alberta, Edmonton, Alberta, Canada Abstract Background: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS. Methods/Results: Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a bioassay, using K562 cells and 51Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230 controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significa